ArticleLife (Basel, Switzerland)2026
A Cross-Sectional Pilot Study of Probable Sarcopenia in Hemodialysis Patients.
Article in Life (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Chronic kidney disease is defined as a progressive pathology that affects more than 10% of the world's population, affecting waste filtration capacity. Sarcopenia, characterized by loss of muscle mass and strength, is a common complication in patients with chronic kidney disease undergoing hemodialysis. It is associated with inflammation, malnutrition and reduced quality of life. Hemodialysis is the fundamental treatment for people with chronic kidney disease, as it is key to the elimination of toxins from the body.
objectiveThe objective of this study was to determine the prevalence of probable sarcopenia in patients with chronic kidney disease in the Dialysis Unit of Extremadura (Spain). MATERIAL AND
methodsThis is a descriptive study in which 33 patients with chronic kidney disease receiving hemodialysis were selected as participants in the assessment of functional capacity and physical fitness. The procedure was performed prior to the dialysis session. Socio-demographic, clinical and physical variables were assessed. The assessment of probable sarcopenia was carried out using manual grip strength test (dynamometry), physical performance (4-meter walk test) and phase angle (PhA) (single frequency 50 Hz bioimpedance). The Charlson Comorbidity Index (CCI) was used to determine the severity of chronic disease and its impact, and analytical variables such as albumin, C-reactive protein (CRP), Neutrophil/Lymphocyte Index (NLI), Lymphocyte-Platelet Index (LPI) and total protein (TP), among others, were also included.
resultsThe prevalence of probable sarcopenia was 93.9% according to the criteria for muscle strength and physical performance (EWGSOP2). PhA showed statistically significant differences between the groups with and without sarcopenia (
conclusionsThere is a high prevalence of probable sarcopenia, associated with decreased handgrip strength and gait speed in patients with chronic kidney disease in hemodialysis. In addition, PhA stands out as an influential factor in the development of sarcopenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.